Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metastasis02:30

Metastasis

5.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.2K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.2K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

13.1K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
13.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-enzymatic RNA Glycation is a Metabolic Sensor of Cellular Stress.

bioRxiv : the preprint server for biology·2026
Same author

Non-Enzymatic MGO-Glycation of SRSF2 Drives RNA Mis-Splicing.

Journal of the American Chemical Society·2026
Same author

Innovative radiotherapies for the treatment of glioblastoma.

Neuro-oncology advances·2026
Same author

Lnc5q21.2, a novel long intergenic RNA, sensitizes colorectal cancer cells to ATR inhibitor by activating Wnt pathway.

Journal of translational internal medicine·2025
Same author

The molecular blueprint of targeted radionuclide therapy.

Nature reviews. Clinical oncology·2025
Same author

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow-up biomarkers for breast cancer.

Molecular oncology·2025

Related Experiment Video

Updated: Sep 20, 2025

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

268

Cancer epitranscriptomics in a nutshell.

Irina Primac1, Audrey Penning1, François Fuks1

  • 1Laboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Centre (U-CRC), Université libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium.

Current Opinion in Genetics & Development
|June 9, 2022
PubMed
Summary

Epitranscriptomics, the study of RNA modifications, is crucial in cancer biology. N6-methyladenosine (m6A) modifications are increasingly linked to cancer progression and offer potential therapeutic targets.

More Related Videos

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
10:41

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues

Published on: April 5, 2018

10.5K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.7K

Related Experiment Videos

Last Updated: Sep 20, 2025

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

268
An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
10:41

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues

Published on: April 5, 2018

10.5K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.7K

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetics

Background:

  • Epitranscriptomics investigates RNA modifications, significantly advancing our understanding of gene regulation.
  • Messenger RNA (mRNA) modifications are now recognized as key players in various biological processes, including cancer pathogenesis.
  • The field of epitranscriptomics is rapidly evolving, revealing critical roles for RNA marks in tumor biology.

Purpose of the Study:

  • To summarize recent advancements in cancer epitranscriptomics.
  • To highlight the role of N6-methyladenosine (m6A) in oncogenic features.
  • To explore the potential of epitranscriptomics as a therapeutic strategy in oncology.

Main Methods:

  • Review of current literature on epitranscriptomics and cancer.
  • Analysis of the contribution of m6A modifications to cancer hallmarks.
  • Discussion of mRNA-modifying enzymes and their biological impact.

Main Results:

  • N6-methyladenosine (m6A) is implicated in tumor growth, invasion, metastasis, stemness, metabolic reprogramming, and the tumor microenvironment.
  • mRNA-modifying enzymes influence biological processes and contribute to cancer hallmarks.
  • Epitranscriptomic alterations are frequently observed in various cancers.

Conclusions:

  • Epitranscriptomics, particularly m6A modification, represents a critical area in cancer research.
  • Targeting mRNA-modifying enzymes and pathways holds significant promise for novel cancer therapies.
  • Further research into epitranscriptomics could unlock new avenues for cancer treatment and management.